

LAW OFFICES
KILYK & BOWERSOX, P.L.L.C.
Intellectual Property Law

RECEIVED
CENTRAL FAX CENTER
JUN 01 2005

LUKE A. KILYK* (PA, DC)
LEONARD D. BOWERSOX
JASBIR SINGH
MATTHEW T. GILL
RALPH T. WEBB* (DC, TX, LA)
SUSANNE M. HOPKINS

53 A East Lee Street
WARRENTON, VA 20186

TEL.: (540) 428-1701
FAC.: (540) 428-1720
(540) 428-1721

FAIRFAX OFFICE
3603-E Chain Bridge Road
Fairfax, Virginia 22030

Email: lkilyk@kbpatentlaw.com
Website: http://www.kbpatentlaw.com

Of Counsel:
LAWRENCE B. BUGAISKY, Ph.D.* (DC)
WILLIAM CHARLES JAMISON, Ph.D.

*Admitted only in states indicated

PLEASE DIRECT CORRESPONDENCE TO OUR WARRENTON OFFICE

FACSIMILE TRANSMISSION COVER SHEET

DATE: June 1, 2005

TO: Examiner Kamal A. Saeed
Group Art Unit 1626
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RE: U.S. Patent Application No. 10/723,208
For: NOVEL ARYLAMINOPROPANE ANALOGUES AND
THEIR USE FOR THE TREATMENT OF GLAUCOMA
Our Ref: 2162 (3010-009-01)

FROM: Luke A. Kilyk, Esq. *LK*

FAC. TEL. NO.: 1-703-872-9306

NUMBER OF PAGES (INCLUDING THIS COVER SHEET): 10

Items Attached: Amendment - 9 pages

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-703-872-9306 on June 1, 2005.

Kim Blum
Name (Print)

Kim Blum
Signature

THE INFORMATION CONTAINED IN THIS MESSAGE IS CONFIDENTIAL INFORMATION INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED. This message may also be an attorney/client communication which is privileged and confidential. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by calling us collect and return the original message to us at the above address by mail. Thank you.

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-703-872-9306 on June 1, 2005.

Kim Blum
Name (Print)


Signature

RECEIVED
CENTRAL FAX CENTER

JUN 01 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: HELLBERG et al.) Examiner: Kamal A. SAEED

Application No.: 10/723,208) Group Art Unit: 1626

Filed: November 26, 2003) Confirmation No.: 8524

Docket No.: 2162 (3010-009-01)) Customer No.: 33432

For: NOVEL ARYLAMINOPROPANE ANALOGUES AND THEIR USE FOR THE TREATMENT OF
GLAUCOMA

AMENDMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

June 1, 2005

Sir:

This Amendment is in response to the Office Action dated April 8, 2005, for which the Examiner has set a three-month period for response, thus making a response due on or before July 8, 2005.

Please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 8 of this paper.